Verastem VSTM
NASDAQ VSTM
$8.14 +0.16 (+1.94%)
As of: Sep 4, 2026 · 3:15 PM EDT

Verastem (VSTM) Research & Development (2011 - 2026)

Verastem (VSTM) posted quarterly Research & Development of $38.2 million for Q1 2026, up 31.1% year-over-year from $29.2 million in Q1 2025, and up 20.66% quarter-over-quarter from $31.7 million in Q4 2025.

Analysis

Verastem (VSTM) Research & Development (2011 - 2026) Analysis & Trends

Verastem's Research & Development history runs 16 years deep, the most recent figure standing at $38.2 million for Q1 2026.

  • In Q1 2026, Research & Development rose 31.1% year-over-year to $38.2 million; the TTM figure through Mar 2026 stood at $123.7 million (up 33.29% YoY), while the FY2025 annual figure was $114.6 million, up 40.9% from the prior year.
  • Research & Development for Q1 2026 stood at $38.2 million, up from $31.7 million in the prior quarter.
  • The five-year high for Research & Development was $38.2 million in Q1 2026, with the low at $10.7 million in Q4 2022.
  • The 5-year median for Research & Development is $18.1 million (2024), against an average of $20.4 million.
  • Peak annual rise in Research & Development reached 109.52% in 2023, while the deepest fall reached 13.4% in 2023.
  • Verastem's Research & Development stood at $10.7 million in 2022, then surged by 109.52% to $22.5 million in 2023, then fell by 7.51% to $20.8 million in 2024, then jumped by 52.2% to $31.7 million in 2025, then rose by 20.66% to $38.2 million in 2026.
  • Business Quant data shows VSTM's Research & Development at $38.2 million in Q1 2026, $31.7 million in Q4 2025, and $29.0 million in Q3 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) R&D (Qtr)
1 Vertex Pharmaceuticals 138.51 Bn 130.66 Bn 2.84 Bn 993.80 Mn
2 Regeneron Pharmaceuticals 85.24 Bn 77.25 Bn 3.93 Bn 1.63 Bn
3 Argenx Se 63.46 Bn 58.28 Bn 1.37 Bn -486.00 Mn
4 Moderna 57.89 Bn 52.75 Bn 52.00 Mn 651.00 Mn
5 Revolution Medicines 44.02 Bn 44.02 Bn - 394.92 Mn
6 BeOne Medicines 39.95 Bn 34.85 Bn 1.53 Bn 612.28 Mn
7 Alnylam Pharmaceuticals 35.49 Bn 32.19 Bn 992.69 Mn 413.13 Mn
8 Royalty Pharma 28.43 Bn 27.59 Bn - 97.90 Mn
9 Insmed 27.39 Bn 26.22 Bn 358.27 Mn 210.03 Mn
10 Verastem 815.95 Mn 679.59 Mn 36.32 Mn 41.34 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 41.34 Mn
Mar 31, 2026 38.22 Mn
Dec 31, 2025 31.67 Mn
Sep 30, 2025 28.99 Mn
Jun 30, 2025 24.79 Mn
Mar 31, 2025 29.15 Mn
Dec 31, 2024 20.81 Mn
Sep 30, 2024 24.75 Mn
Jun 30, 2024 18.06 Mn
Mar 31, 2024 17.71 Mn
Dec 31, 2023 22.50 Mn
Sep 30, 2023 13.95 Mn
Jun 30, 2023 12.89 Mn
Mar 31, 2023 12.02 Mn
Dec 31, 2022 10.74 Mn
Sep 30, 2022 11.29 Mn
Jun 30, 2022 14.89 Mn
Mar 31, 2022 13.64 Mn
Dec 31, 2021 11.40 Mn
Sep 30, 2021 9.33 Mn